

XI SIMPOSIO INTERNACIONAL CÁNCER DE MAMA DE SANTIAGO 2018

CENTRO PARQUE - 18 AL 20 DE ABRIL - SANTIAGO - CHILE



PROGRAM

Organiza:



Patrocinan:



XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

INVITED PROFESSORS

Dr. May Chomali Director Médico de Clínica Las Condes.

Kevin S. Hughes MD. Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Associate Professor of Surgery Harvard Medical School, Medical Director Bermuda Cancer Genetics and Risk Assessment Clinic.

Carlos Arteaga, MD. Medical Oncologist, Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center. Associate Dean of Oncology Programs, Dallas, USA.

Jeniffer Bellon, MD. Radiation Oncologist, Director, Breast Radiation Oncology Institute Physician. Associate Professor of Radiation Oncology, Harvard Medical School Dana Farber Cancer Institute and Harvard Medical School; Harvard, USA.

Alex Prat, MD. Medical Oncologist, Head Medical Oncology Department, Associate Professor Hospital Clínic, University of Barcelona, Barcelona, Spain.

Mothaffar Rimawi, MD. Medical Oncologist, Medical Director Smith Breast Center, Baylor College of Medicine, Houston, USA.

Pascal Baltzer, MD. Radiologist. Department of Biomedical Imaging and Image-Guided Therapy, Medical University and General Hospital of Vienna, Austria.

Eva Ciruelos, MD. Medical Oncologist. Breast Cancer Unit, Hospital 12 de Octubre, Associated professor, Complutense University, Madrid, Spain.

Mariana Chavez-Macgregor, MD. Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.

José Masià, MD. Plastic Surgeon, Head, Plastic and Reconstructive Surgery Department. Hospital de la Santa Creu i Sant Pau and Hospital del Mar (Universitat Autònoma de Barcelona), Barcelona, Spain.

Allen Gabriel, MD. Plastic Surgeon, Legacy Salmon Creek Medical Center and PeaceHealth Southwest Medical Center, Vancouver, USA.

Laura García Estévez, MD. Head, Breast Unit, Comprehensive Oncology Center Clara Campal, (CIOCC), HM Hospitals, Madrid, Spain.

Sergio Quezada, PhD. Group Leader, Immune Regulation and Tumor Immunotherapy Lab, University College of London Cancer Institute, England. (TBC).

Elsa Pereira, MD. Immunologist, Medical Director, MSD Chile, Chile.

Roberto Torres, MD. Medical Oncologist, National Cancer Institute Hospital, Chile.

César Sánchez, MD. Medical Oncologist, Catholic University School of Medicine, Chile.

Laura Itriago, MD. Medical Oncologist, Director for Cancer Prevention, Clinical Cancer Center, Clínica Las ondas, Chile.

Christine Adaniel, MD. Medical Oncologist, Sotero del Rio Hospital and Clinical Cancer Center, Clinica Las Condes, Chile.

Álvaro Ibarra, MD. Pathologist, Head Pathology Service, Clinica Las Condes, Chile.

Verónica Robert, Psychologist, Head Psychology Cancer Patients Support Program, Clinica Las Condes, Chile.

Adela Camus, MD. Gynecologist, Human Reproductive Center, Gynecologic Department, Clinica Las Condes, Chile.

Antonio Sola, MD. Radiation Oncologist, Clinical Cancer Center, Clinica Las Condes, Chile.

Ariel Fariña, MD. Radiation Oncologist, Chile.

Javier Retamales, MD. Radiation Oncologist, Chile.

Felipe Carvajal, MD. Radiation Oncologist, Chile.

Ricardo Armisen, MD. Center for Excellence in Precision Medicine Pfizer, Chile.

Soledad Torres, MD. Breast Surgeon, Centro Integral de la Mama, Clinica Las Condes, Chile.

Susana Benítez, MD. Plastic Surgeon, Department of Surgery, Clinica Las Condes, Chile.

Hernando Paredes, MD. Breast Surgeon, Centro Integral de la Mama, Clinica Las Condes, Chile.

Nuvia Aliaga, MD. Breast Surgeon, Centro Integral de la Mama, Clinica Las Condes, Chile.

Andrés Mascaró, MD. Plastic Surgeon, Department of Surgery, Clinica Las Condes, Chile.

Juan M. Donaire, MD. Breast Surgeon, Centro Integral de la Mama, Clinica Las Condes, Chile.

Augusto León, MD. Oncology Surgeon, Catholic University, School of Medicine, Santiago, Chile.

Ma. Cristina Gastó, MD. Supportive Care Unit, Clinical Cancer Center, Clinica Las Condes, Chile.

XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

THIRD DRAFT XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM EDUCATIONAL PRE SYMPOSIUM MEETINGS

Wednesday April 18th, 2018

08:00 - 08:30 Registration

08:00 - 12:00 **NEW ADVANCES IN RECONSTRUCTIVE SURGERY**

08:30 - 08:40 Welcome and Introduction. **Dr. Hernando Paredes**

Breast reconstruction and radiotherapy. Alternatives for breast reconstruction in irradiated tissue.

Chairman: Andrés Mascaro MD.

08:40 - 09:10 **Plenary Session:** Immediate breast reconstruction in previously irradiated breast.

Allen Gabriel MD.

09:10 - 09:25 Radiotherapy over implant. **Nuvia Aliaga MD.**

09:25 - 09:40 Radiotherapy over tissue expander. **Hernando Paredes MD.**

09:40 - 10:10 Delayed breast reconstruction after radiotherapy: planning the alternatives.

> 09:40 - 09:55 Using flaps. **Susana Benítez MD.**

> 09:55 - 10:10 Using implants. **Juan M. Donaire MD.**

10:10 - 10:40 Coffee break

Breast Reconstruction using ADMs - Chairwoman: Susana Benítez MD.

10:40 - 11:00 The evolution of breast reconstruction, from sub-pectoral to pre-pectoral. **José Masià MD.**

11:00 - 11:20 Early outcomes in submuscular versus prepectoral ADM assisted breast reconstruction.

Allen Gabriel MD.

11:20 - 11:40 Early outcomes in cost-effectiveness and functionality in pre-pectoral ADM covered implant versus sub-muscular breast reconstruction. **José Masià MD.**

11:40 - 12:00 Pre-pectoral breast reconstruction. How to avoid complications? **Allen Gabriel MD.**

12:00 - 12:20 Q&A

12:20 - 13:30 Lunch and Industry Symposium.

Wednesday April 18, 2018 (afternoon)

THE PENDING CHALLENGES OF DCIS

13:30 - 13:50 Is over-diagnosis a problem? **Augusto León, MD.**

13:50 - 14:10 Active surveillance/de-escalation of therapy approach for low risk DCIS and the importance of margins. **Kevin S. Hughes MD.**

14:10 - 14:30 Radiotherapy for DCIS. **Antonio Sola, MD. (Clinica Las Condes, Chile)**

HOW TO SUPPORT OUR SURVIVING PATIENTS

14:35 - 14:55 The emotional and sexual problems of breast cancer survivors. **Verónica Robert, Ps.**

14:55 - 15:15 How to manage late side effects in surviving patients, including life style. **Laura Itriago, MD.**

15:15 - 15:35 Prevention of chemotherapy induced alopecia and potential role of cooling caps.

Christine Adaniel, MD.

XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

15:35 - 16:00 Coffee break

RADIOTHERAPY CONTROVERSIES

16:00 - 16:20 Accelerated Partial breast irradiation: Intra, pre-or post-surgery. **Ariel Fariña, MD. (FALP)**

16:20 - 16:40 Radiotherapy and breast reconstruction. **Javier Retamales, MD. (Universidad de Chile)**

16:40 - 17:00 State of the Art in Hyper-fractionated radiotherapy schedules. **Felipe Carvajal, MD. (Instituto Nacional del Cancer, Chile)**

ADVANCES IN BREAST RADIOLOGY

Pascal Baltzer, MD.,

Prof, Medical University of Vienna, department of biomedical imaging and image guided therapy.

17:00 - 17:20 Limitations of Breast MRI and how to address them. **Pascal Baltzer, MD.**

17:20 - 17:40 MRI as a biomarker for diagnostic and prognostic factors. **Pascal Baltzer, MD.**

17:40 - 18:00 MRI for screening purposes: ultrashort enhanced protocols or DWI only? **Pascal Baltzer, MD.**

18:00 - 19:30 Images work-shop

XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

08:00 - 18:00 Registration

Thursday April 19th, 2018 (MORNING)

08:30 - 08:40 Opening remarks and welcome

Soledad Torres, MD.; Hernando Paredes, MD.; Jose M. Reyes MD.

WHAT HAVE WE LEARNED FROM NEO-ADJUVANT TREATMENT?

08:40 - 09:00 The benefits of neo-adjuvant therapy according to molecular subtypes.

Mariana Chavez-Macgregor, MD.

09:00 - 09:20 Neo-adjuvant endocrine treatment: How to select the appropriate patient and how to evaluate response. **Mothaffar Rimawi, MD.**

09:30 - 10:15 Submitted Papers (10 minutes for presentation 5 minutes for Q&A)

10:15 - 10:35 MRI in the assessment of neo-adjuvant treatment: response assessment and impact on treatment. **Pascal Baltzer, MD.**

11:00 - 11:08 Opening remarks **May Chomali, MD. Medical Director, Clinica Las Condes**

11:10 - 11:30 Is surgery of the breast & the axilla mandatory in complete responders to neo-adjuvant treatment? **Kevin S. Hughes MD.**

11:30 - 11:50 Radiotherapy after neo-adjuvant treatment. **Jennifer Bellon MD.**

11:50 - 12:10 Adjuvant medical treatment after neo-adjuvant treatment. For whom and with what drugs? **Carlos Arteaga, MD.**

12:10 - 13:05 Clinical Cases Discussion (loco-regional) **Coordinator: Soledad Torres, MD.**

13:05 - 14:05 Industry Symposium

XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

Thursday April 19, 2018 (AFTERNOON)

OVERCOMING ENDOCRINE RESISTANCE

- 14:10 - 14:30 Palbociclib, rivociclib or amebaciclib: Are all the same? Mechanisms of action and clinical results. [Mariana Chavez-Macgregor, MD.](#)
- 14:30 - 14:50 CDK4/6 inhibitors, how do they work? Why only in ER+ tumors? Are they different? Mechanisms of resistance. [Dr. Carlos Arteaga](#)
- 14:50 - 15:10 When and whom benefit from the use of everolimus or other PIK3CA inhibitors? [Eva Ciruelos, MD.](#)
- 15:20 - 15:40 SERMs, SERDs, SSH for the management of endocrine sensitive metastatic breast cancer: How do they fit in the same patient? [Aleix Prat, MD.](#)

ESCALATING AND DE-ESCALATING TREATMENT INTENSITY

- 16:00 - 16:20 Role of the pathologist for breast cancer treatment: de-escalation and escalation of therapy [Álvaro Ibarra, MD.](#)
- 16:20 - 16:40 Molecular platforms. Utility and assay comparison. [Laura García Estévez, MD.](#)
- 16:40 - 17:10 Submitted papers
- 17:10 - 17:40 Endocrine therapy: 10 years or more for all ER/PgR positive patients? Or Less than 10 years for some of them? [Mothaffar Rimawi, MD.](#)
- 17:40 - 18:00 Which patients benefit from axillary dissection? [Kevin S. Hughes MD.](#)
- 18:00 - 18:20 Which patients do not benefit from radiotherapy? [Jennifer Bellon MD.](#)
- 18:20 - 18:40 De-escalating systemic treatment in HER2+ disease [Aleix Prat MD.](#)
- 18:40 - 20:00 Industry Symposium

Friday, April 20th (MORNING)

FACING PROBLEMS OF VERY YOUNG PATIENTS WITH BREAST CANCER

- 08:15 - 08:35 Fertility preservation for women with or at risk of breast cancer: For mutation carriers, for women with breast cancer diagnoses. [Adela Camus, MD.](#)
- 08:35 - 08:55 What to do with tamoxifen in women who desire pregnancy. [César Sánchez, MD.](#)
- 09:00 - 09:20 Role of ovary suppression in the adjuvant management of hormone receptor positive HER-2 negative very young patients [Roberto Torres, MD.](#)
- 09:40 - 10:00 Role of adjuvant chemotherapy for hormone receptor positive, HER-2 negative, very young patients. [Mothaffar Rimawi, MD.](#)
- 10:00 - 10:20 Mechanisms of resistance to endocrine therapy: Bedside to bench approaches to identify them (PIK3CA, HER2 mutations, etc.). [Dr. Carlos Arteaga](#)
- 10:20 - 10:40 Coffee Break

XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

METASTATIC AND RECURRENT DISEASE

- 10:40 - 11:00 When to introduce supportive care in advanced breast cancer [Cristina Gastó, MD.](#)
- 11:00 - 11:20 Personalized medicine in breast cancer: The role of next generation sequencing
[Ricardo Armisen, MD.](#)
- 11:20 - 11:40 PARP inhibitors: Only useful for triple negative disease? Clinical data and future perspectives.
[Aleix Prat, MD.](#)
- 11:40 - 12:00 CDK4/CDK6 for HER-2 positive and triple negative disease: State of the research.
[Carlos Artega, MD.](#)
- 12:00 - 13:00 Clinical cases Discussion (Advanced Disease)
- 13:00 - 14:00 Industry Symposium and Lunch Time
- 14:00 - 14:20 New data and new drugs for HER-2 disease [Eva Ciruelos, MD.](#)
- 14:20 - 14:40 Molecular classification of triple negative disease: which one is best? [Aleix Prat, MD.](#)
- 14:40 - 15:00 Immune therapy for triple negative breast cancer [Elsa Pereira, MD.](#)
- 15:00 - 15:20 Immune therapy: The future for breast cancer? [Sergio Quezada, PhD. \(TBC\)](#)
- 15:50 - 16:10 Management of local recurrence after conservative surgery. Is mastectomy mandatory?
[Soledad Torres, MD](#)
- 16:10 - 16:50 Role of surgery in the management of oligo-metastatic breast cancer.
Does the molecular sub-type matter?
- 16:10 - 16:30 The surgeon perspective. [Juan M. Donaire, MD.](#)
- 16:30 - 16:50 The medical oncologist point of view. [Mariana Chavez-Macgregor MD.](#)
- 16:50 - 18:20 Plenary conference: Genetic testing for hereditary breast cancer. [Kevin S. Hughes MD.](#)